12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
Crispr Therapeutics Ag (CRSP)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 8,973,064 | $353,179,787 | +20% | 2.94% |
| 2. | Orbis Investment Management William B. Gray | 1,476,119 | $58,100,044 | 0.31% | |
| 3. | EcoR1 Capital Oleg Nodelman | 1,389,276 | $54,681,903 | 2.06% | |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,308,011 | $51,483,313 | +56% | 0.54% |
| 5. | SR One Capital Simeon George | 1,048,951 | $41,286,711 | 10.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.95 | 27,461 | Large Shareholder | 5,380,940 | 2018-12-27 | Filing | |
| $24.89 | 12,737 | Large Shareholder | 5,353,479 | 2018-12-26 | Filing | |
| $24.97 | 53,655 | Large Shareholder | 5,340,742 | 2018-12-24 | Filing | |
| $23.18 | 11,742 | Large Shareholder | 5,287,087 | 2018-12-24 | Filing | |
| $22.91 | 2,603 | Large Shareholder | 5,275,345 | 2018-12-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $52.80 | 333 | 7,062 | 2025-02-19 | Filing | ||
| $52.80 | 6,928 | 189,973 | 2025-02-19 | Filing | ||
| $55.05 | 11,640 | 196,901 | 2025-02-18 | Filing | ||
| $52.80 | 1,947 | 74,880 | 2025-02-19 | Filing | ||
| $53.85 | 9,595 | 73,002 | 2025-02-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,743,523 | $344,145,065 | 0.06% | |
| 2. | 2,759,326 | $108,607,071 | 0% | |
| 3. | 2,745,676 | $108,069,807 | 1.17% | |
| 4. | 2,745,676 | $108,069,807 | 0.07% | |
| 5. | 2,491,525 | $98,066,424 | 0% |
News See All
Cathie Wood's Stock Portfolio: 2025 Stock Picks
Cathie Wood is one of Wall Street's most contentious figures.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
10 Worst ARK Stocks To Buy According to Short Sellers
Cathie Wood of ARK Investment is one of Wall Street's most well-known hedge fund bosses.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
10 Best Genomics Stocks To Buy Right Now
Genomics is the study of genes and how they function.
ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024
ARK Investment Management LLC, more commonly known as ARK Invest, is an American investment management firm headquartered in St. Petersburg, Florida, that oversees several actively managed ETFs.
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds
The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics...
Billionaire Hedge Funds
